Tag Archives: TM123

Switchable CAR-T Updates from Arcellx, GEMoaB, and AbClon; Carisma Therapeutics Presents Their CAR-Macrophage and CAR-Monocyte Programs; AACR 2021 Day 4

On the fourth day of AACR 2021 Week I, several key clinical / preclinical updates were presented from GEMoaB, Arcellx, AbClon, and Carisma Therapeutics. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.